AbbVie's Phase 3 CANOVA Study Of Venetoclax Plus Dexamethasone For Relapsed Or Refractory Multiple Myeloma Did Not Demonstrate A Significantly Improved Progression-free Survival, The Primary Endpoint Of The Trial
Portfolio Pulse from Benzinga Newsdesk
AbbVie's Phase 3 CANOVA study of Venetoclax plus Dexamethasone for relapsed or refractory multiple myeloma did not meet its primary endpoint of significantly improved progression-free survival. Although patients receiving VenDex showed improvement in median PFS of 9.9 months compared to 5.8 months with the combination of study comparator pomalidomide and dexamethasone (PomDex), the results did not reach statistical significance.
September 29, 2023 | 11:18 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbbVie's Phase 3 CANOVA study did not meet its primary endpoint, which may negatively impact investor sentiment and the company's stock price in the short term.
Clinical trial results are a significant driver of pharmaceutical companies' stock prices. The failure to meet the primary endpoint in a Phase 3 trial could be seen as a setback, potentially leading to a negative impact on AbbVie's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100